New
Service for TodaysSeniorsNetwork.com
readers...roll mouse over, click on
highlighted links in stories to review items
from Amazon
Now, keep up to date
with daily feeds of newly posted stories
about America's Seniors...click on the box
to the left
Expression
patterns of MicroRNAs appear altered in
Colon Cancer, and associated with poor
outcomes
Newswise — Preliminary
research has found an association between
certain microRNA expression patterns and
poor survival and treatment outcomes for
colon cancer, according to a study in the
January 30 issue of JAMA.
Colon cancer is a major
cause of cancer death worldwide. Colorectal
cancer is the third most common and second
leading cause of cancer death in the United
States.
“Even though 5-year mortality rates
have modestly declined over the last 3
decades, there is still a need to identify
new prognostic biomarkers and therapeutic
targets for this disease,” the authors
write.
They add that microRNAs have
potential as diagnostic biomarkers and
therapeutic targets in cancer.
MicroRNAs are 18 to 25
nucleotide, noncoding RNA (ribonucleic acid)
molecules that have been found to regulate a
variety of cellular processes and may also
have a role in the development of cancer
cells.
The prognostic potential of microRNAs
has been demonstrated for chronic
lymphocytic leukemia, lung cancer and
pancreatic cancer, according to background
information in the article.
No study has
evaluated the association between microRNA
expression patterns and colon cancer
prognosis or therapeutic outcomes.
Aaron J. Schetter,
Ph.D., M.P.H., and Curtis C. Harris, M.D.,
of the National Cancer Institute, National
Institutes of Health, Bethesda, Md., and
colleagues evaluated microRNA profiles of
colon tumors and paired nontumorous tissue
to study their potential role in tumor
formation, diagnosis and therapeutic outcome
in colon cancer.
The study included 84
patients from Maryland; associations were
validated in a second, independent group of
113 patients from Hong Kong.
Thirty-seven microRNAs
were differentially expressed in tumor
tissues by microRNA microarray analysis in
the Maryland test cohort. Expression
patterns of five tested microRNAs were
validated in the Hong Kong cohort.
“The
discriminatory power of 5 microRNAs to
differentiate between tumor and nontumorous
tissue suggests that predictable and
systematic changes of microRNA expression
patterns may occur during tumorigenesis and
may be representative of sporadic colon
adenocarcinomas,” the authors write.
“… we found systematic
differences in microRNA expression patterns
between colon tumors and paired nontumorous
tissue. Tumors with high expression of
miR-21 [a microRNA] was associated with poor
survival outcome and poor response to
adjuvant chemotherapy in 2 independent
cohorts, independent of staging and other
clinical covariates suggesting that miR-21
may be a useful diagnostic biomarker for
colon adenocarcinomas and survival prognosis
including response to therapy.”
“Additional studies are
required to demonstrate a causal link with
miR-21 and the progression of colon cancer
to determine the potential of miR-21 as
either a biomarker or therapeutic target,”
the researchers write.